Trial Profile
A Randomized, Open-label, Phase II Open Platform Study Evaluating the Efficacy and Safety of Novel Spartalizumab (PDR001) Combinations in Previously Treated Unresectable or Metastatic Melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Canakinumab (Primary) ; Capmatinib (Primary) ; Ieramilimab (Primary) ; Ribociclib (Primary) ; Spartalizumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms PLATforM
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 08 Mar 2024 This trial has been discontinued in Italy according to European Clinical Trials Database record.
- 09 Feb 2023 This trial has been discontinued in Spain (Global end date: 30 Dec 2022).
- 27 Jan 2023 Status changed from active, no longer recruiting to completed.